Focus on GU Cancers: Current Clinical Experience With PD-1/PD-L1 Immune Checkpoint Inhibitors

Download this slideset from Scot Niglio, MD to see an overview of how IO biomarkers are currently used for patients with GU cancers, with key data on immunotherapy approaches for bladder cancer, RCC, and prostate cancer.
Scot Niglio, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.09 MB
Released: July 9, 2020


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
Merck Sharp & Dohme Corp

Related Content

Downloadable slideset reviewing the latest data on immunotherapy for patients with newly diagnosed advanced urothelial carcinoma, from Clinical Care Options (CCO)

person default Thomas Powles, MBBS, MRCP, MD Released: September 21, 2020

Downloadable slideset on the latest data on treatment for patients with progressive urothelial carcinoma and insights on new horizons for immunotherapy in urothelial carcinoma, from Clinical Care Options (CCO)

person default Alain Ravaud, MD, PhD Released: September 21, 2020

Commentary from Elizabeth R. Plimack, MD, MS on new treatment options, including erdafitinib and enfortumab vedotin, for urothelial cancer from CCO

Elizabeth R. Plimack, MD, MS Released: September 15, 2020

From Clinical Care Options (CCO), expert commentary by Dr Richard Finn on the use of atezolizumab plus bevacizumab for advanced HCC

Richard Finn, MD Released: September 15, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?